Effectiveness of Screening Using Fecal Occult Blood Testing and Colonoscopy on the Risk of Colorectal Cancer: The Japan Public Health Center-based Prospective Study

Overview

Journal J Epidemiol

Specialty Public Health

Date 2021 May 31

PMID 34053963

Citations 4

Authors

Kenta Tanaka

Tomotaka Sobue

Ling Zha

Tetsuhisa Kitamura

Norie Sawada

Motoki Iwasaki

Manami Inoue

Taiki Yamaji

Shoichiro Tsugane

Affiliations

Soon will be listed here.

Abstract

Background: Few cohort studies have used multiple surveys of screening attendance to simultaneously evaluate the effectiveness of fecal occult blood test (FOBT) and colonoscopy.

Methods: We analyzed data of 30,381 middle-aged Japanese adults from a population-based prospective cohort study. Information on FOBT and colonoscopy was obtained from three questionnaire surveys (every 5 years). We classified the subjects into three groups: the FOBT (15,649 subjects), screening colonoscopy (2,407 subjects), and unscreened (12,325 subjects) groups. We used the unscreened group as the reference group to compare the mortality and incidence of colorectal cancer (CRC).

Results: During the 14-year follow-up, 64, 12, and 104 CRC deaths were identified in the FOBT, screening colonoscopy, and unscreened groups, respectively. The risk of CRC death reduced with increasing the number of FOBTs (P for trend = 0.02) and was reduced by 44% in the subjects screened twice or thrice using FOBT (hazard ratio [HR] 0.56; 95% confidence interval [CI], 0.33-0.94). Significant decreases were seen for the incidence of CRC but not seen for the incidence of non-advanced CRC in the FOBT group. Concerning the screening colonoscopy, subjects screened at the start of follow-up showed a 69% reduced risk of CRC death (HR 0.31; 95% CI, 0.10-0.9996). Significant decreases were also seen for the incidence of CRC and non-advanced CRC in the subjects screened at the start of follow-up.

Conclusion: FOBT, depending on the number of FOBTs, and colonoscopy, depending on recency, reduced the risk of death due to CRC and the incidence of CRC.

Citing Articles

Rare germline chromosome 1 duplication identified in young male with colon cancer: a case report investigating causality.

Byrjalsen A, Garcia S, Borgwardt L, Wadt K, Gerdes A, Hansen T J Gastrointest Oncol. 2024; 15(5):2316-2322.

PMID: 39554577 PMC: 11565109. DOI: 10.21037/jgo-24-148.

Possibility of determining high quantitative fecal occult blood on stool surface using hyperspectral imaging.

Ikematsu H, Takara Y, Nishihara K, Kano Y, Owaki Y, Okamoto R J Gastroenterol. 2024; 60(1):77-85.

PMID: 39441401 PMC: 11717890. DOI: 10.1007/s00535-024-02163-2.

Indirect Effects of Municipal Public Health Nurse Workforce on Cancer Standardized Mortality Ratios Mediated by Cancer Screening Rates.

Kodama S, Hinokuma R Public Health Nurs. 2024; 42(1):70-79.

PMID: 39415500 PMC: 11700944. DOI: 10.1111/phn.13451.

The Effectiveness of Screening Total Colonoscopy for Preoperative Patients with Gastric Cancer.

Koseki Y, Hikage M, Terashima M, Notsu A, Furukawa K, Fujiya K Ann Surg Oncol. 2023; 31(2):762-771.

PMID: 37925659 DOI: 10.1245/s10434-023-14538-5.

References

Hewitson P, Glasziou P, Watson E, Towler B, Irwig L . Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008; 103(6):1541-9. DOI: 10.1111/j.1572-0241.2008.01875.x. View

Rossi P, Vicentini M, Sacchettini C, Di Felice E, Caroli S, Ferrari F . Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy. Am J Gastroenterol. 2015; 110(9):1359-66. DOI: 10.1038/ajg.2015.240. View

Wolf A, Fontham E, Church T, Flowers C, Guerra C, LaMonte S . Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018; 68(4):250-281. DOI: 10.3322/caac.21457. View

Katsoula A, Paschos P, Haidich A, Tsapas A, Giouleme O . Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer: A Meta-analysis. JAMA Intern Med. 2017; 177(8):1110-1118. PMC: 5710432. DOI: 10.1001/jamainternmed.2017.2309. View

Parente F, Vailati C, Boemo C, Bonoldi E, Ardizzoia A, Ilardo A . Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy. Dig Liver Dis. 2014; 47(1):68-72. DOI: 10.1016/j.dld.2014.09.015. View

Saito H, Soma Y, Koeda J, Wada T, Kawaguchi H, Sobue T . Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer. 1995; 61(4):465-9. DOI: 10.1002/ijc.2910610406. View

Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian Z . Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013; 369(12):1095-105. PMC: 3840160. DOI: 10.1056/NEJMoa1301969. View

Oshima A . A critical review of cancer screening programs in Japan. Int J Technol Assess Health Care. 1994; 10(3):346-58. DOI: 10.1017/s0266462300006590. View

Mandel J, Church T, Bond J, Ederer F, Geisser M, Mongin S . The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000; 343(22):1603-7. DOI: 10.1056/NEJM200011303432203. View

10.

von Karsa L, Patnick J, Segnan N . European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Executive summary. Endoscopy. 2012; 44 Suppl 3:SE1-8. DOI: 10.1055/s-0032-1309822. View

11.

Bibbins-Domingo K, C Grossman D, Curry S, Davidson K, Epling Jr J, Garcia F . Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 315(23):2564-2575. DOI: 10.1001/jama.2016.5989. View

12.

Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A . Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366(8):697-706. DOI: 10.1056/NEJMoa1108895. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Watanabe S, Tsugane S, Sobue T, Konishi M, Baba S . Study design and organization of the JPHC study. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol. 2002; 11(6 Suppl):S3-7. PMC: 11858366. DOI: 10.2188/jea.11.6sup_3. View

15.

Larsen M, Njor S, Ingeholm P, Andersen B . Effectiveness of Colorectal Cancer Screening in Detecting Earlier-Stage Disease-A Nationwide Cohort Study in Denmark. Gastroenterology. 2018; 155(1):99-106. DOI: 10.1053/j.gastro.2018.03.062. View

16.

Saito H, Soma Y, Nakajima M, Koeda J, Kawaguchi H, Kakizaki R . A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test. Oncol Rep. 2000; 7(4):815-9. DOI: 10.3892/or.7.4.815. View

17.

Tsugane S, Sawada N . The JPHC study: design and some findings on the typical Japanese diet. Jpn J Clin Oncol. 2014; 44(9):777-82. DOI: 10.1093/jjco/hyu096. View

18.

Lee K, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S . Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev. 2007; 31(1):3-11. DOI: 10.1016/j.cdp.2006.11.002. View

19.

Ventura L, Mantellini P, Grazzini G, Castiglione G, Buzzoni C, Rubeca T . The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis. 2013; 46(1):82-6. DOI: 10.1016/j.dld.2013.07.017. View

20.

Chiu H, Chen S, Yen A, Chiu S, Fann J, Lee Y . Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015; 121(18):3221-9. PMC: 4676309. DOI: 10.1002/cncr.29462. View